Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy

Leuk Res. 2020 Sep:96:106406. doi: 10.1016/j.leukres.2020.106406. Epub 2020 Jun 25.

Authors

Michael E Kallen¹, Rima Koka², Zeba Singh², Gabriela Sanchez-Petitto³, Qamar U Zaman⁴, Jean A Yared³, Vu H Duong³

Affiliations

¹ Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, United States. Electronic address: [email protected].
² Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, United States.
³ Department of Medicine, Division of Hematology / Oncology, University of Maryland School of Medicine, Baltimore, MD, United States.
⁴ University of Pittsburgh Medical Center, Western Maryland, Cumberland, MD, United States.

PMID: 32604058
DOI: 10.1016/j.leukres.2020.106406

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aminopyridines / adverse effects*
Cellulitis / etiology
Cellulitis / pathology*
Humans
Isocitrate Dehydrogenase / antagonists & inhibitors
Isocitrate Dehydrogenase / genetics*
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / pathology
Male
Middle Aged
Mutation*
Neutrophils / drug effects
Neutrophils / pathology*
Prognosis
Skin Diseases / etiology
Skin Diseases / pathology*
Triazines / adverse effects*

Substances

Aminopyridines
Triazines
enasidenib
IDH2 protein, human
Isocitrate Dehydrogenase